Synthesis and evaluation of novel 8,6-fused bicyclic peptidomimetic compounds as interleukin-1b converting enzyme inhibitors

Procter & Gamble Pharmaceuticals, Inc., 8700 Mason-Montgomery Road, Mason, OH 45040, USA.
Bioorganic & Medicinal Chemistry Letters (Impact Factor: 2.42). 01/2006; 15(24):5434-8. DOI: 10.1016/j.bmcl.2005.08.109
Source: PubMed


Two novel 8,6-fused bicyclic peptidomimetic ring systems were synthesized utilizing olefin metathesis as the key reaction for the formation of the eight-membered ring. Both peptidomimetic scaffolds were further elaborated into potent ICE inhibitors, with numerous compounds exhibiting caspase-1 IC(50)s less than 10nM.

9 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: This is a review of papers published in the year 2003 that focus on the synthesis, reactivity, or properties of compounds containing a carbon-transition metal double or triple bond. (c) 2004 Elsevier B.V. All rights reserved.
    Coordination Chemistry Reviews 05/2005; 249(9-10):999-1084. DOI:10.1016/j.ccr.2004.10.009 · 12.24 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The interleukin (IL)-1 cytokine family includes 11 distinct members that are related in their genomic and protein structures. The initial members of this family, IL-1α and IL-1β, were discovered over two decades ago and are now considered as prototypic pro-inflammatory cytokines. Their activity is downregulated by a third family member, termed IL-1-receptor antagonist (IL-1ra). Another IL-1 family cytokine that was also identified early on is IL-18, an agonist cytokine possessing potent immunostimulatory activities. Subsequently, sequence homology searches in DNA databases led to the discovery of genes that encode additional family members. IL-1 cytokines exert their function through structurally related cell surface receptors that have a Toll/IL-1 receptor (TIR) module in their intracellular region and one to three copies of immunoglobulin (Ig)-like domains in their extracellular region. At present, 11 members of the IL-1 receptor family are known. A hallmark of IL-1 receptor signalling, which is mediated via the TIR domain, is the activation of the transcription factor NF-κB and the mitogen-activated protein kinases (MAPK). Owing to their possible roles in immune disease mechanisms, IL-1 and its relatives have long been considered as potential targets of therapeutic intervention in inflammatory and autoimmune conditions. Strong evidence for the importance of IL-1 in pathogenic inflammation was recently provided by the clinical use of a recombinant form of human IL-1ra for the treatment of rheumatoid arthritis and certain autoinflammatory syndromes. The discovery and characterisation of the IL-1 families of cytokines and receptors, as well as the exploration of their therapeutic potential, has generated a large body of patent literature over the past few years. Here, this literature is reviewed and discussed in the context of current research findings.
    Expert Opinion on Therapeutic Patents 06/2006; 16(7):879-912. DOI:10.1517/13543776.16.7.879 · 4.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: 1-tert-Butyl-2-(allyloxymethyl)aziridine has been transformed for the first time diastereoselectively into cis-3,5-di(bromomethyl)-4-tert-butylmorpholine via an electrophile-induced ring closure using bromine in dichloromethane. The latter morpholine has been used as a substrate for the synthesis of the corresponding 3,5-di(methoxymethyl)morpholine and 3,5-di(cyanomethyl)morpholine upon nucleophilic displacement of both bromo atoms. Further evaluation of this protocol toward the synthesis of 4-arylmethyl- and 4-alkylmethyl-3,5-di(bromomethyl)morpholines showed that the premised cyclization of the corresponding 2-(allyloxymethyl)aziridines into 3,5-di(bromomethyl)morpholines only proceeded well for the N-neopentylmorpholine, which was subsequently transformed into a 3-oxa-7-thia-9-azabicyclo[3.3.1]nonane derivative. Also, in some other cases, the desired 3,5-di(bromomethyl)morpholines were isolated in low yields and transformed into the corresponding 3,5-di(cyanomethyl)morpholines.
    The Journal of Organic Chemistry 07/2006; 71(12):4678-81. DOI:10.1021/jo060313y · 4.72 Impact Factor
Show more

Similar Publications